These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 34074331)

  • 1. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
    Campochiaro C; Allanore Y
    Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease.
    Aragona CO; Versace AG; Ioppolo C; La Rosa D; Lauro R; Tringali MC; Tomeo S; Ferlazzo G; Roberts WN; Bitto A; Irrera N; Bagnato G
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current advances in the treatment of systemic sclerosis.
    Bukiri H; Volkmann ER
    Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists.
    Ferrari HM; Kale-Pradhan P; Konja J; Dierker M; Martirosov AL
    Ann Pharmacother; 2023 Dec; ():10600280231213672. PubMed ID: 38095621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.
    Fernández-Lázaro D; Iglesias-Lázaro M; Garrosa E; Rodríguez-García S; Jerves Donoso D; Gutiérrez-Abejón E; Jorge-Finnigan C
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.
    Campochiaro C; Lazzaroni MG; Bruni C; Zanatta E; De Luca G; Matucci-Cerinic M
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221116408. PubMed ID: 36051631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
    Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
    Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].
    Lescoat A; Jouneau S; Uzunhan Y; Jégo P; Cottin V; Hachulla E
    Rev Med Interne; 2022 Jun; 43(6):365-374. PubMed ID: 35181160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
    Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
    Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
    J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
    Hoffmann-Vold AM; Brunborg C; Airò P; Ananyeva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Valentini G; Kowal-Bielecka O; Allanore Y; Distler O;
    Chest; 2023 Mar; 163(3):586-598. PubMed ID: 36244404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.
    Vonk MC; Smith V; Sfikakis PP; Cutolo M; Del Galdo F; Seibold JR
    Autoimmun Rev; 2021 Dec; 20(12):102978. PubMed ID: 34718159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
    Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
    Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
    Bruni C; Campochiaro C; de Vries-Bouwstra JK
    Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
    Mendoza FA; Allawh T; Jimenez SA
    Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.
    Chong WH; Saha BK; Beegle S
    Am J Med Sci; 2023 Feb; 365(2):198-204. PubMed ID: 35276077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.